source
- NYU's Neil Vasan steps down as acting chair of FDA's oncology drug advisory committeeNeil Vasan, a professor at NYU, has announced he is stepping down from his role as acting chair of the FDA’s Oncologic Drugs Advisory Committee (ODAC). Vasan has participated in 22 ODAC meetings a…
- FDA warns investors that advisory panel reviews do not guarantee drug approval, cites concerns at Capricor and ReplimuneThe FDA issued a reminder to investors that the outcomes of advisory committee meetings are not final decisions on a drug’s fate. This week the agency released briefing documents highlighting conc…